Launch of LENVIMA® in Brazil
LENVIMA®’s first steps in the Brazilian market.
Montevideo, Uruguay April 23, 2018. From April 19th to 22nd, specialists related to the study of the thyroid gland and its pathologies, such as Thyroid Cancer, gathered in Campos do Jordão (SP) for one more EBT (Brazilian Thyroid Meeting). Grupo Biotoscana took the opportunity to launch LENVIMA® in this year‘s edition, where the event brought together more than 2,000 physicians divided among the specialties of Endocrinologists, Head and Neck Surgeons, Oncologists and Nuclear Medicine Specialists.
Grupo Biotoscana also had an Official Launch Symposium of LENVIMA® during EBT in which Dr. Ana Hoff, an endocrinologist specialized in the topic, was the speaker. Dr. Ana, who was one of the SELECT Study PIs (Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid), is deeply experienced and recognized not only in the treatment of Thyroid Cancer, but also with the usage of LENVIMA® (Lenvatinibe). She currently works at two national reference centers named ICESP and Rede D‘Or. The symposium reached its full capacity: 170 Physicians attended the launch symposium. The theme was focused on the different stages of the disease, from the diagnosis, which has been increasing in recent decades, to innovative systemic therapies for patients with metastatic disease, such as LENVIMA®.
It was an intense week in Campos do Jordão, but the expectancy couldn’t be better. Physicians were glad to know that they now have one more option to treat patients with Metastatic Thyroid Cancer with responses like no other drug has.
LENVIMA® (lenvatinib) is a novel multiple receptor tyrosine kinase inhibitor (orally administered molecular-targeted agent) discovered and developed by Eisai. Launched as a treatment for refractory thyroid cancer in the United States, Japan and Europe in 2015 and has been granted orphan drug status (a drug for rare diseases) for the treatment of thyroid cancer by the regulatory authorities in each of these regions. LENVIMA® is also indicated to treat adults with a form of advanced kidney cancer.